Alteration of the Physicochemical Properties Of

Total Page:16

File Type:pdf, Size:1020Kb

Alteration of the Physicochemical Properties Of Proc. Nati. Acad. Sci. USA Vol. 75, No. 2, pp.,784-788, February 1978 Biochemistry Alteration of the physicochemical properties of triphosphoinositide by nicotinic ligands (neuromuscular blockers/hydrophobicity/phosphatidylinositol bisphosphate) TAE MOOK CHO, JUNG SOOK CHO, AND HORACE H. LOH Langley Porter Neuropsychiatric Institute and Department of Pharmacology, University of California, San Francisco, California 94143 Communicated by Choh Hao Li, December 2,1977 ABSTRACT The concentrations of nicotinic drugs required from cerebral cortex by De Robertis et al. (7). Chemical de- to effect a 50% transfer of triphospho[3H]inositide from an terminations confirmed that P3inositide is present in this re- aqueous phase to a nonaqueous phase closely approximated ceptor fraction and suggested that P3inositide is the major their concentrations for both in vivo neuromuscular blocking activity and binding to purified nicotinic receptors, and corre- component responsible for the binding of nicotinic ligands lated well (correlation coefficient = 0.95) with their biological (6). activities measured by other workers in an Electrophorus The present study describes selective alterations in the electroplax preparation. The triphospho[3Hjinositide transfer physicochemical properties of P3inositide on interaction with induced by nicotinic ligands was dependent on the lipid con- various nicotinic ligands. The alterations have been shown to centration and was potentiated by Ca +. The affinity constants be related to the neuromuscular blocking activity of these li- of 45Ca2+ for triphosphoinositide were similar to those for the purified nicotinic receptor. These and other findings suggest gands. The results suggest that P3inositide may function as a the possibility that triphosphoinositide (phosphatidylinositol binding component of the nicotinic cholinergic receptor. is a site of the nicotinic bisphosphate) binding receptor. MATERIALS AND METHODS Recently, Cavallito (1) and others (2, 3) have reported that Chemicals. P3inositide was isolated by the method of Michell electrostatic bond formation between the cationic portion of et al. (8), further purified using triethylaminoethyl-cellulose nicotinic ligands and the anionic site of the cholinergic receptor column chromatography, and identified by the method of is essential for pharmacological activity. Cavallito further Gonzalez-Sastre and Folch-Pi (9), using thin-layer chroma- suggested that the highly charged phosphate macromolecules tography and visualization by iodine, which yielded a single may be more closely related to the nicotinic receptor than are spot with an RF value the same as the reported one. The P3- monovalent anions such as carboxylate, phosphate, and sulfate inositide spot was removed and the phosphate content was (4). From structural considerations of triphosphoinositide determined by Bartlett's method (10). On the basis of the (Psinositide; phosphatidylinositol bisphosphate), a membrane phosphate determination, the P3inositide was over 95% pure. acidic lipid with a maximum of five negative charges, it is P3[3H]inositide (specific activity 3 Ci/mmol) was prepared by theoretically possible that the molecule could interact with a C. T. Peng (School of Pharmacy, University of California, San variety of structurally unrelated nicotinic ligands. For example, Francisco) at the Lawrence Laboratories (Berkeley, CA). the.cationic nitrogen and carbonyl oxygen of a drug such as 45CaCl2 (20 Ci/g) was obtained from New England Nuclear carbachol could bind to an anionic oxygen atom in the phos- (Boston, MA). phate group and to a hydroxyl group of the inositol ring, re- The following chemicals were purchased from Sigma spectively. Similarly, the distance between the two cationic Chemical Co.: d-tubocurarine chloride, decamethonium nitrogen atoms in the hexamethonium molecule is similar to chloride, trimethylbenzylammonium chloride, succinylcholine the distance between two anionic oxygen atoms of the phos- chloride, hexamethonium chloride, carbachol chloride, pilo- phates in the 4 and 5 positions of the inositol ring. Furthermore, carpine, methacholine chloride, (+)-muscarine chloride, 5- the distance between the quaternary nitrogen atoms in cho- hydroxytryptamine, dopamine, epinephrine, norepinephrine, linergic ligands such as decamethonium, succinylcholine, gal- and histamine. Nicotine, 1,1-dimethylphenylpiperazonium lamine, and d-tubocurarine matches the distance between the iodide, and lobeline were purchased from K & K Laboratories; two anionic oxygen atoms of the phosphate group in positions gallamine triethiodide from Davis and Geck, American Cy- 1 and 4 or 1 and 5 of the inositol ring. These theoretical con- anamid Co.; and mecamylamine from Merck, Sharp and siderations are supported by experimental data showing that Dohme Research Laboratories. a-Bungarotoxin was a gift from P3inositide binds nicotinic agonists and antagonists with high C. C. Chang of National Taiwan University (Taipei, Republic affinities, and that the dissociation constants obtained are of China). comparable to those reported for the same agents binding to Preparation of P3inositide Micelles. P3[3H]inositide was purified nicotinic receptor (5). Of the membrane acidic lipids mixed with unlabeled P3inositide in a mixture of chloroform examined, only P3inositide selectively binds di[14C]methyl- and methanol (2:1) and the solution was then taken down to d-tubocurarine ([14CJDMTC), and the chromatographic be- dryness on a rotary vacuum evaporator, after which the dried havior of the [14C]DMTC-PNinositide complex on a Sephadex P,3inositide powder was suspended in 5 ml of Tris-HCI buffer LH-20 column (6) is identical to the behavior of the DMTC (2 mM, pH 7.4) and allowed to swell for an hour. The P3inosi- complex formed with the proteolipid receptor fraction isolated tide was sonicated for 1 min and then diluted with the same The costs of publication of this article were defrayed in part by the Abbreviations: P3inositide, triphosphoinositide (phosphatidylinositol payment of page charges. This article must therefore be hereby marked bisphosphate); DMTC, dimethyl-d-tubocurarine; IC50, concentration "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate required to induce a 50% transfer of P3inositide from aqueous to this fact. nonaqueous phase. 784 Downloaded by guest on September 26, 2021 Biochemistry: Cho et al. Proc. Natl. Acad. Sci. USA 75 (1978) 785 buffer to give an appropriate final P3inositide concentra- tion. 'or Interface P3[3H]inositide Transfer Studies. Five tenths milliliter of 9 the P3[3H]inositide micelle preparation was added to 0.5 ml of Tris buffer containing drug and/or cation at room temperature. 8 This aqueous solution was mixed with 1 ml of heptane on a Vortex mixer (speed setting at 5) for 1 min and the mixture was 0 7 centrifuged at 1500 X g for 10 min. A 0.5-ml aliquot of the x aqueous phase mixed with 5 ml of Scintiverse cocktail solution E6 (Fisher Scientific Co.) was assayed in a Beckman liquid scin- tillation counter to determine P3[3H]inositide activity. The 5 radioactivity in the nonaqueous phase (heptane plus interphase) 0. was determined by subtracting the radioactivity in the aqueous 0o phase from the total amount added. The percent of drug-in- I duced P3[3H]inositide transferred from the aqueous phase to 31 K\ie Heptane phase the nonaqueous phase was calculated by using the following 0 ° ~Oto. equation: at---la 2 F 4__hi % of P3[3H]inositide transferred I Aqueous phase radioactivity without - radioactivity with drug I I I I I I I I drug in aqueous phase in aqueous phase x 100 1 2 3 4 5 6 7 8 9 10 radioactivity without drug [Decamethoniuml, MM FIG. 1. Distribution of P3[3H]inositide in the presence and ab- in aqueous phase sence of decamethonium. The influence of various concentrations of 45Ca2+ Binding to P3inositide. One hundred milliliters of decamethonium on the distribution of P3[3H]inositide between the 45Ca2+ was mixed with 100 ml of the nonra- aqueous phase, the heptane phase, and the interface was determined (2 puM) prepared by measurement of the radioactivity in the buffer and heptane com- dioactive P3inositide micelles (20 jg/ml). An aliquot of the ponents. The amount ofP3[3H]inositide at the interface was indirectly mixture (0.5 ml) was added to a 0.5-ml solution containing deduced by calculations, subtracting the measured radioactivities various concentrations of unlabeled calcium or neuromuscular from the total. blocking agents and the aqueous solution was mixed with 1 ml of heptane on a Vortex mixer (speed at 5) for 1 min. The mix- K1 = 2.7 AtM, K2 = 25 MM, and K3 = 350 AM. These data ture was centrifuged at 1500 X g for 10 min and the radioac- suggest that in the presence of 100 AM calcium ion only the tivity of 45Ca2+ in the lower phase was determined by the same binding sites with the two lower dissociation constants (K1 and method described for the P3[3H]inositide transfer studies. 00 r- RESULTS Distribution of P3[3H]inositide. The radioactive P3inositide A'S in both the heptane and aqueous phases was determined in the presence and absence of decamethonium, and the amount of 8C /O labeled P3inositide at the interphase was obtained by sub- of. tracting the measured radioactivities from the total added. As shown in Fig. 1, the P3[3H]inositide in the aqueous phase de- 4O~0) creased with increasing concentration of the decamethonium (A added, while the radioactivity in the nonaqueous phases in- a) 60 creased, particularly in the interphase. c La 3+ ICa2t 0' Effects of Calcium and Lanthanum Ions on P3[3H]inosi- 'a (a tide Transfer. Fig. 2 shows that both calcium and lanthanum, *0 a calcium antagonist, promoted P3[3H]inositide transfer from 0 the aqueous to the nonaqueous phase in a concentration-de- 40I pendent manner. The concentration of lanthanum required to I- 0/ induce a 50% transfer from the aqueous to the nonaqueous 4 phase (IC50) was approximately 250 times less than that of calcium. The P3[3H]inositide transfer was also determined with 20 increasing concentrations of decamethonium and d-tubocu- 0 rarine in the presence and absence of 100 AM calcium ion, 0l which by itself did not significantly induce the transfer (Fig.
Recommended publications
  • Use of Chemical Chelators As Reversal Agents for Drug
    (19) TZZ_ _ZZZ_T (11) EP 1 210 090 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/724 (2006.01) A61K 31/194 (2006.01) 18.06.2014 Bulletin 2014/25 A61P 39/04 (2006.01) (21) Application number: 00964006.1 (86) International application number: PCT/EP2000/007694 (22) Date of filing: 07.08.2000 (87) International publication number: WO 2001/012202 (22.02.2001 Gazette 2001/08) (54) USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCK VERWENDUNG VON CHEMISCHEN CHELATOREN ZUR UMKEHRUNG VON PHARMAKOLOGISCH-INDUZIERTER NEUROMUSKULÄRER BLOCKIERUNG UTILISATION D’AGENTS CHIMIQUES CHELATANTS COMME AGENTS DE NEUTRALISATION DU BLOCAGE NEUROMUSCULAIRE PROVOQUE PAR DES MEDICAMENTS (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU AU-A- 3 662 895 MC NL PT SE • B DESIRE: "Inactivaton of sarin and soman by (30) Priority: 13.08.1999 EP 99306411 cyclodextrins in vitro" EXPERIENTIA, vol. 43, no. 4, 1987, pages 395-397, XP000907287 (43) Date of publication of application: • B. DESIRE: "Interaction of soman with beta- 05.06.2002 Bulletin 2002/23 cyclodextrin" FUNDAMENTAL AND APPLIED TOXICOLOGY, vol. 7, no. 4, 1986, pages 647-657, (73) Proprietor: Merck Sharp & Dohme B.V. XP000911170 2031 BN Haarlem (NL) • C. MAY: "Development of a toxin-binding agent as a treatment for tunicamycinuracil toxicity: (72) Inventors: protection against tunicamycin poisoning of • BOM, Antonius, Helena, Adolf sheep" AUSTRALIAN VETERINARY JOURNAL, Ratho, Midlothian EH28 8NY (GB) vol. 76, no.
    [Show full text]
  • Expression of Multiple Populations of Nicotinic Acetylcholine
    EXPRESSION OF MULTIPLE POPULATIONS OF NICOTINIC ACETYLCHOLINE RECEPTORS IN BOVINE ADRENAL CHROMAFFIN CELLS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Bryan W. Wenger, B.A. The Ohio State University 2003 Dissertation Committee: Approved by: Professor Dennis B. McKay, Advisor Professor R. Thomas Boyd ________________________ Advisor Professor Popat N. Patil College of Pharmacy Professor Lane Wallace, Ph.D. ABSTRACT The importance of the role of nAChRs in physiological and pathological states is becoming increasingly clear. It is apparent that there are multitudes of nAChR subtypes with different expression patterns, pharmacologies and functions that may be important in various disease states. Therefore, a greater understanding of nAChR subtypes is essential for potential pharmacological intervention in nAChR systems. Bovine adrenal chromaffin cells are a primary culture of a neuronal type cell that express ganglionic types of nAChRs whose activation can be related to a functional response. While much is known about the outcome of functional activation of adrenal nAChRs, little work has been done in characterizing populations of nAChRs in adrenal chromaffin cells. These studies characterize the pharmacology and regulation of populations of nAChRs found in bovine adrenal chromaffin cells. The primary findings of this research include 1) the characterization of an irreversible antagonist of adrenal nAChRs, 2) the discovery of
    [Show full text]
  • Muscle Relaxants Femoral Arteriography.,,>
    IN THIS ISSUE: , .:t.i ". Muscle Relaxants fI, \'.' \., Femoral ArteriographY.,,> University of Minnesota Medical Bulletin Editor ROBERT B. HOWARD, M.D. Associate Editors RAY M. AMBERG GILBERT S. CAMPBELL, M.D. ELLIS S. BENSON, MD. BYRON B. COCHRANE, M.D. E. B. BROWN, PhD. RICHARD T. SMITH, M.D. WESLEY W. SPINK, MD. University of Minnesota Medical School J. 1. MORRILL, President, University of Minnesota HAROLD S. DIEHL, MD., Dean, College of Medical SciencBs WILLIAM F. MALONEY, M.D., Assistant Dean N. 1. GAULT, JR., MD., Assistant Dean University Hospitals RAY M. AMBERG, Director Minnesota Medical Foundation WESLEY W. SPINK, M.D., President R. S. YLVISAKER, MD., Vice-President ROBERT B. HOWARD, M.D., Secretary-Treasurer Minnesota Medical Alumni Association BYRON B. COCHRANE, M.D., President VIRGIL J. P. LUNDQUIST, M.D., First Vice-President SHELDON M. LAGAARD, MD., Second Vice-President LEONARD A. BOROWICZ, M.D., Secretary JAMES C. MANKEY, M.D., Treasurer UNIVERSITY OF MINNESOTA Medical Bulletin OFFICIAL PUBLICATION OF THE UNIVERSITY OF MINNESOTA HOSPITALS, MINNE· SOTA MEDICAL FOUNDATION, AND MINNESOTA MEDICAL ALUMNI ASSOCIATION VOLUME XXVIII December 1, 1956 NUMBER 4 CONTENTS STAFF MEETING REPORTS Current Status of Muscle Relaxants BY J. Albert Jackson, MD., J. H. Matthews, M.D., J. J. Buckley, M.D., D.S.P. Weatherhead, M.D., AND F. H. Van Bergen, M.D. 114 Small Vessel Changes in Femoral Arteriography BY Alexander R. Margulis, M.D. AND T. O. Murphy, MD.__ 123 EDITORIALS .. - -. - ---__ __ _ 132 MEDICAL SCHOOL ACTIVITIES ----------- 133 POSTGRADUATE EDUCATION - 135 COMING EVENTS 136 PIIb1ished semi.monthly from October 15 to JUDe 15 at Minneapolis, Minnesota.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born Et A1
    US007265099B1 (12) United States Patent (10) Patent N0.: US 7,265,099 B1 Born et a1. (45) Date of Patent: *Sep. 4, 2007 (54) USE OF CHEMICAL CHELATORS AS Tarver, G. et al “2-O-Substituted cyclodextrins as reversal REVERSAL AGENTS FOR DRUG-INDUCED agents . ” Bioorg. Med. Chem. (2002) vol. 10, pp 1819-1827.* NEUROMUSCULAR BLOCK Zhang, M. “Drug-speci?c cyclodextrins . ” Drugs of the Future (2003) vol. 28, no 4, pp 347-354.* (75) Inventors: Antonius Helena Adolf Bom, Lee, C. “Structure, conformation, and action of neuromuscular Midlothian (GB); Alan William Muir, blocking drugs” Brit. J. Anesth. (2001) vol. 87, no 5, pp 755-769.* Lanark (GB); David Rees, Gothenburg B Desire: “Inactivation of sarin and soman by cyclodextrins in (SE) vitro” EXPERIENTIA, vol. 43, No. 4, 1987, pp. 395-397. B. Desire: “Interaction of soman with beta-cyclodextrin” Funda (73) Assignee: Organon N.V., Oss (NL) mental and Applied Toxicology, vol. 7, No. 4, 1986, pp. 647-657. ( * ) Notice: Subject to any disclaimer, the term of this C. May: “Development of a toxin-bindng agent as a treatment for patent is extended or adjusted under 35 tunicamycinuracil toxicity: protection against tunicamycin poison U.S.C. 154(b) by 0 days. ing of sheep” Australian Veterinary Journal, vol. 76, No. 11, 1998 pp. 752-756. This patent is subject to a terminal dis K. Uekama: “Effects of cyclodextrins on chlorpromaZine-induced claimer. haemolysis and nervous systems responses” J. Pharm. Pharmacol., vol. 33, No. 11, 1981, pp. 707-710. (21) Appl. No.: 10/049,393 T. Irie: “Protective mechanism of beta-cyclodextrin for the hemolysis induced With phenothiazine neuroleptics in vitro” J.
    [Show full text]
  • Clinical Pharmacokinetics of Muscle Relaxants
    i ,I .. / ,""- Clinical Pharmacokinetics 2: 330-343 (1977) © ADIS Press 1977 Clinical Pharmacokinetics of Muscle Relaxants L.B. Wingard and DR. Cook Departments of Pharmacology and Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania SUl1lmary Muscle relaxants are commonly used as an adjunct to general anaesthesia and to facilitate ventilator care in the intensive care unit. The muscle relaxants are unique in that the degree of neurol1luscular blockade can be directly measured. Thus, for some of the muscle relaxants it is possible to correlate the degree of neuromuscular blockade with the plasma concentration of drug. This quantilalive pllGrmacokinelic approach has been applied primarily to d­ tubocurarine and to a lesser extent to suxamethonium (succinylcholine), gallamine and pan­ curoniul1l. The pharl1lacokinetic information for the other relaxants is mostly descriptive and incomplete. The variation in drug concentration over time is in.fluenced by the distribution, metabolism and excretion of drug. Metabolism by plasma cholinesterase plays a maJor role in the termina­ tion (~f action of suxamethonium. Although pancuronium is partly metabolised its major metabolites have moderate pharmacological activity. The other relaxants are excreted through the kidney. For gallamine and dimethyl-tubocurarine, renal excretion appears to be the only means qf eliinination. However, biliary excretion probably provides an alternative route of elimination for d-tubocurarine and pancuronium. In patients with impaired renal function the duration qf neuromusClilar blockade may be markedly prolonged following standard doses of gallamine or dimethyl-tubocurarine, may be slightly prolonged following standard doses of pancumnium, and is near normal following standard doses qf d-tubocurarine. Following large or repeated doses q(pancuronium or d-tubocurarine, the duration q{ neuromuscular blockade may be markedly prolonged.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Pharmacological Review of Chemicals Used for the Capture of Animals
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Proceedings of the 7th Vertebrate Pest Vertebrate Pest Conference Proceedings Conference (1976) collection March 1976 PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS Peter J. Savarie U.S. Fish and Wildlife Service Follow this and additional works at: https://digitalcommons.unl.edu/vpc7 Part of the Environmental Health and Protection Commons Savarie, Peter J., "PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS" (1976). Proceedings of the 7th Vertebrate Pest Conference (1976). 41. https://digitalcommons.unl.edu/vpc7/41 This Article is brought to you for free and open access by the Vertebrate Pest Conference Proceedings collection at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Proceedings of the 7th Vertebrate Pest Conference (1976) by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS* PETEIR J. SAVARIE, U.S. Fish and Wildlife Service, Building 16, Federal Center, Denver, Colorado 80225 ABSTRACT: A review of the literature reveals that over 60 chemicals have been used for the capture of wi l d animals, but only 30 of the most widely used chemicals are discussed in the present paper. For practical considerations these chemicals can be c l a ssified as being either (l) neuromuscular blocking agents, or (2) central nervous system (CNS) depressants. Some common neuromuscular blocking agents are d-tubocurarine, gallamine, succiny1choline, and nicotine. M99 and its derivatives, phencyclidine, and xylazine are some of the more commonly used CNS depressants. Neuromuscular blocking agents have a relatively rapid onset and short duration of action but they do not possess sedative, analgesic, or anesthetic properties.
    [Show full text]
  • PRODUCT MONOGRAPH TRACRIUM7 (Atracurium Besylate)
    PRODUCT MONOGRAPH TRACRIUM7 (Atracurium besylate) 10 mg/mL Injection Intravenous Skeletal Neuromuscular Blocking Agent AbbVie Corporation DATE OF PREPARATION: 8401 Trans Canada Highway November 1, 2012 St-Laurent (QC) CANADA H4S 1Z1 DATE OF LATEST REVISION: DATE OF REVISION: Control No. 158344 NOTE: TRACRIUM is a trademark of the Glaxo group of companies, AbbVie Corporation licensed use - 2 - PRODUCT MONOGRAPH NAME OF DRUG TRACRIUM7 (Atracurium Besylate Injection) THERAPEUTIC CLASSIFICATION Intravenous Skeletal Neuromuscular Blocking Agent ACTIONS AND CLINICAL PHARMACOLOGY TRACRIUM (atracurium besylate) is a nondepolarizing, intermediate-duration, skeletal neuromuscular blocking agent. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively to cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine. The duration of neuromuscular blockade produced by atracurium besylate is approximately one-third to one-half the duration seen with d-tubocurarine, metocurine and pancuronium at equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium besylate doses. INDICATIONS AND CLINICAL USE TRACRIUM (atracurium besylate) is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. CONTRAINDICATIONS TRACRIUM (atracurium besylate) is contraindicated in patients known to have a hypersensitivity to atracurium. Use of atracurium from multiple-dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known sensitivity to benzyl alcohol.
    [Show full text]
  • D-TUBOCURARINE CHLORIDE for CHEST SURGERY by T
    Postgrad Med J: first published as 10.1136/pgmj.24.276.514 on 1 October 1948. Downloaded from 514 POST GRADUATE MEDICAL JOURNAL October I948 all round sense to other methods but even in its go wrong and create dangers that are just as great, most refined standards it is doubtful whether, if not greater because they are more insidious alone, it serves fully the requirements of the long than those associated with the older, and simpler and severe operations now carried out in the methods. abdomen. Success with inhalational anaesthesia The observation so often made in the past that demands a much higher degree of technical dex- the choice of the anaesthetist is more important terity and more fundamental physiological and than the choice of anaesthetic is indeed truer pharmacological knowledge on the part of the today than ever for the scope for unintentional administrator than ever before. In the hands of foolishness and possible disaster has widened the. inexperienced there are many things that may considerably. A SYSTEM OF ANAESTHESIA USING D-TUBOCURARINE CHLORIDE FOR CHEST SURGERY By T. CECIL GRAY, M.D., D.A., F.F.A., R.C.S. et- Reader in Anaesthesia, University of Liverpool ; Atiaesthetist, Liverpool Chest Surgical Centre The exciting and exploratory spirit which has mechanical disorders in the respiration are likely become apparent of recent years in surgery would to occur. On the affected side the lung will collapsecopyright. have been frustrated were it not that anaesthesia on inspiration and expand on expiration. This advanced contemporaneously. In no field has this phenomenon has been described as 'paradoxical spirit in surgery and this progress in anaesthesia respiration' and it results in a certain amount of been more in evidence than in the radical treat- vitiated air passing from the collapsed to the ment of disease of the thoracic viscera.
    [Show full text]